NASDAQ:AKBA
Akebia Therapeutics, Inc.
Akebia Therapeutics, Inc.'s revenue grew 47.5% in fiscal 2025 to $236.2M while operating margin rose to 9.9%, its highest in 10 years. Free cash flow was $67.7M, 28.7% of revenue, and the diluted share count rose 21.9%.Summary generated from Akebia Therapeutics, Inc.'s SEC filings. Latest annual report filed Feb 26, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$236.2M
Revenue growth+47.5%
Revenue, 5-yr CAGR−4.3%
Gross margin83.3%
Operating margin9.9%
Net margin−2.3%
ROICn/a
Return on equityn/a
Debt / equity1.48
Free cash flow$67.7M
FCF margin28.7%
Share count change+21.9%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 212 | 292 | 195 | 160 | 236 |
| Operating income | −265 | −81 | −46 | −50 | 23 |
| Net income | −282 | −94 | −52 | −69 | −5 |
| Free cash flow | −253 | −73 | −23 | −41 | 68 |
Recent filings
- 4Insider transaction report
Aug 10, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 5, 2026 - 8-KResults of operations and financial condition
Aug 5, 2026 - 4Insider transaction report
Jul 1, 2026 - 8-KRegulation FD disclosure
Jun 30, 2026 - 8-KResults of a shareholder vote
Jun 22, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 7, 2026 - 8-KResults of operations and financial condition
May 7, 2026